QUÉBEC CITY, Nov. 19,
2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that it has
commenced an underwritten public offering of units
(the "Offering"), consisting of common shares and warrants to
purchase common shares. The pricing and number of Units as well as
the exercise price and duration of the warrants will be determined
in the course of marketing.
Canaccord Genuity is acting as sole book-running
manager for the proposed Offering. The proposed Offering is subject
to customary conditions, including the approval of the Toronto
Stock Exchange ("TSX") and The NASDAQ Stock Market ("NASDAQ"), and
there can be no assurance as to whether or when the proposed
Offering may be completed, or as to the actual size or terms of the
Offering. The Company has no intention of listing the
warrants on the TSX or NASDAQ.
The Offering is being conducted pursuant to the
Company's effective shelf registration statement on Form F-10
filed with the U.S. Securities and Exchange Commission (the "SEC"),
its corresponding Canadian base shelf prospectus and an exemption
from the Autorité des marches financiers permitting the
Company to offer common shares and warrants in the United States. The proposed offering will
be made only by means of a preliminary prospectus supplement, a
final prospectus supplement and the accompanying short form base
shelf prospectus. When available, copies of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying short form base shelf prospectus may be obtained upon
request by contacting Canaccord Genuity Inc., Attention: Syndicate
Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone
at (617) 371-3900. Electronic copies of the preliminary prospectus
supplement, the final prospectus supplement and the accompanying
short form base shelf prospectus will also be available free of
charge at www.sedar.com and www.sec.gov, respectively.
This press release does not constitute an
offer to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical
company engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds from
drug discovery to regulatory approval. For more information, visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking
statements made pursuant to the safe harbour provisions of the U.S.
Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks and uncertainties that
could cause the Company's actual results to differ materially from
those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and
resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy
data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical
trials, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, unless
required to do so by a governmental authority or by applicable
law.
SOURCE Aeterna Zentaris Inc.